Plain-English translation of NCT07155226 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is a first-in-human trial testing a new medication called for people with advanced blood cancers that have stopped responding to standard treatments. The study has two main parts: one tests the medication alone at different dose levels to find the safest and most effective dose, and another tests how the medication works when combined with an antifungal drug. Researchers want to understand how safe this treatment is, how your body processes it, and whether it can help control your cancer.
People with certain advanced blood cancers — particularly those with specific genetic changes — often run out of treatment options when standard therapies stop working. This medication is designed to target a specific pathway that is overactive in these cancers, offering hope for patients who currently have few alternatives.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will come to a research center multiple times to receive the medication and have your health monitored closely. In the first part of the study, different groups of patients receive increasing doses of the medication to determine the safest level. In the second part, patients receive the medication alone first, then combined with another drug. You will have regular blood tests, physical exams, and disease assessments to see how you are responding and to watch for any side effects. The study team will track how your body processes the medication and whether your cancer is improving.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States